VIDUNI Multidisciplinary Research Journal (VMRJ)
vmrj.vidhyadeepuni.ac.in
ISSN: XXXX-XXXX(Online)

A SUCCESSIVE PROPAGATION: AMALGAMATION OF AI WITH PATHOLOGY

Pranjal P. Gujarathi*

Vidhyadeep Institute of Pharmacy,

Vidhyadeep University, Anita, Surat, Gujarat-394110

Abstract

The research in the domain of pharmacology has been revolutionized after the introduction of artificial intelligence. The novel drug search and individualized medication are greatly affected by the use of Artificial Intelligence (AI). Concerning the pharmacology field, the AI algorithms scrutinize the huge medical data and assist in identifying the probable drug targets, drug reprofiling, in-silico screening, toxicity forecasting, clinical trials, and pharmacovigilance. The identification, trial setup, and instantaneous data crunching were revamped after the introduction of AI, which led to improved safety and efficacy outputs. The adverse effects and drug interactions are well monitored during the post-marketing surveillance by the AI-enabled tools. AI uses machine learning. DL models and neural networks (NN) are adopted to expedite this work. Nevertheless, ratification of AI in pharmacological research heightened ethical issues related to digital data privacy, managing algorithm greediness and clarity, getting medical authorization, and preserving human stewardship in decision-making. The considerable deployment of all AI demands a resilient framework and ethical codes. An incorporation of AI with pharmacological research is propitious, with the amalgamation of trending techniques such as omics science providing an emergent prospect for P4 treatment and targeted treatment. The linkage among the industry, academia, and regulatory bodies is crucial for the ethical execution of AI in drug research. The perpetual progress in AI techniques and training programs will give wings to scientists and healthcare professionals to completely exploit AI's ability, which will lead to upgraded patient outcomes and innovative pharmacotherapy.

Keywords: Artificial intelligence, Deep and Machine Learning, Pharmacology, Toxicity, Pharmacovigilance

1. Introduction

Artificial intelligence is an imitation of human sagacity in a digitally programmed form to give performance like humans. The various tasks, such as optical impression, speech identification, adjudging, and language translation, can be performed by artificial intelligence after the development of algorithms and computer programs.(Li et al., 2024; Xiao & Zhang, 2023). The metamorphic headway in pharmacological exploration has transpired due to the augmentation of ML and DL models that overcome various drug development bottlenecks with increased efficiency, enhanced productivity, and cost-effectiveness. AI assisted in optical screening, drug designing, and binding engagement modeling. Consequently, AI aids in target identification, hit recognition, ADME, and toxicity forecasting, lead optimisation, and drug repurposing. (Vallance & Smart, 2006). The simultaneous evolution of AI and pharmacology leads to strategic alliances and the growth of AI in the field of pharmacology. (So & Karplus, 1996b, 1996a).

The QSAR modelling in pharmacy uses the neural network techniques previously; now, there is at least some variation or advancements, which include more standard data sets and research community building, more distinct descriptors, and a variety of applications in pharmacology are outlined below. (Su et al., 2019). Pharmacology is an intricate study dealing with large-scale computing, data statistics, and analysis. A variety of AI techniques have been utilised in pharmacology research for pharmacokinetic data prediction and clinical pharmacology studies. This paper will shed light on the application of AI in this field and introduce the latest research methods and models.(Obrezanova, 2023).

2. Domains where AI can be effectively utilised in pharmacological studies

2.1. Prediction of the pharmacokinetics of the drug

To study the absorption, distribution, metabolism, and excretion, it is necessary to ensure the efficacy of the drug. Therefore, we can significantly decrease the chemical searching space, enhance the success rate of drug development, and reduce its cost by the application of AI technologies to develop predictive models for pharmacokinetics, and validate ADME characteristics as well as physicochemical properties for drug candidates in the early stage of drug development. (Dulsat et al., 2023). The following section highlights various case studies and AI used to forecast the PK. The blood-brain barrier permeability can be predicted by the DNN, RNN, and CNN (Martínez Mora et al., 2022). DNN is also utilised to forecast the inhibition of CYP450s. The molecular images can be used to predict the *in vitro* clearance using a multi-task CNN. (Sharma et al., 2023). These case studies validate that modelling

with neural networks is generally utilised to forecast the ADME and physicochemical characteristics of compounds.

The advancement in AI, with the integration of multiple models, can forecast numerous essential characteristics of ADME. ADMETlab. ADMETlab2.0, admetSAR, admetSAR2.0, FAF-Drugs4, FP-ADMER, Intepretable-ADMET, and HelixADMET are a few exemplary examples of integrative AI models that are used to foresee the PK of drug candidates.(Venkatraman, 2021; Wei et al., 2022; Xiong et al., 2021). ADMETlab can forecast an extensive coverage with the best accuracy and precision because it has 31 ADME endpoints predicted in version 1.0 and 88 in version 2.0 (Dong et al., 2018). The ADMET version 1.0 refines computational efficiency by providing graphs to illustrate molecules rather than traditional descriptor-based representations. The interpretable ADMET gives a graph convolutional neural network and a graph attention network, while the Helix ADMET utilizes graph neural networks.(S. Zhang et al., 2022). The extensive adoption of these ADMET forecasting techniques denotes the effectiveness of deep learning and graph neural networks for ADMET prediction.

Table 1 Illustration of Various AI databases used in Pharmacological research



2.2. Toxicity prediction

The futuristic toxic effects of the drug candidate can be avoided by predicting toxicity during the development phase. (Paul et al., 2021). Traditionally, toxicity studies can be done through the *in vitro* analysis, followed by the preclinical toxicity study guidelines, which require a high cost. Various toxicity prediction in silico tools, such as LimTOx, pkCSM, admetSAR, and Toxtree, are available. (Yang et al., 2019). AI-enabled approaches foresee the toxic nature recon on the analogy among the entities or on the input commands. The National Institute of Health, Environmental Protection Agency (EPA). And the USFDA has arranged a TOX21 data provocation to scrutinize the toxicity of 12,701 environmental agents and drugs. A DeepTox is an exemplary form of AI to anticipate toxic drugs by employing the ML algorithm. It can forecast the static as well as dynamic characteristics of the drug entity, and can foresee the toxicity depending on the 2500 toxicophore characters. (Mayr et al., 2016).

The safety targets of 656 marketed drugs against 73 unintended drug targets that can produce adverse effects were assessed by SEA. Another example, ToxPred, is utilized to forecast the toxicity and synthesis practicability of small organic molecules, with an accuracy of 72% (Pu et al., 2019). TargeTox and PrOCTOR are accessible sources for predicting toxicity. This tool is trained using an RF model and considers drug-likeness character, molecular character, and target-based character, generating the ProOCTOR score.

2.3. AI in drug repurposing

AI-enabled drug repurposing involves a network-based approach and DL algorithms such as DNN and CNN to study the new uses of already existing drugs. (Kang et al., 2023; Wang et al., 2021; W. Zhang et al., 2018; Y. Zhang et al., 2022). AI performed this task by scrutinizing the diversified data and the way of the drug-disease relationship to order and foresee a capable drug repurposing candidate. Gottlieb prepared a PREDICT classification model by use of logistic regression, and many similarities contribute to forecasting drug-disease relationships, depending on the ML.(Gottlieb et al., 2011; Napolitano et al., 2013). Another research utilised gene expression signature, drug structures, and target proteins to compute drug likelihood and train a multiclass vector machine model for drug-disease relation forecasting. (Napolitano et al., 2013)Table 2 gives a portrait of the databases used in pharmacological research

Table 2: Database in Pharmacological Research

Name of database	Portrayal	Use
LinkeOmic	Digital repository for oncology clinical and molecular data., Collect multi-omics and mass spectrometry protein profiling data related to cancer	Target discrimination
Deep Map portal	Forum for analytical and optical tools for oncology, having cancer cell lines and genetic information	Target acquisition
Therapeutic target database	Databank of connection medications and identified biopharmaceuticals, nucleic acids, and diseases	Target recognition
DUD-E	An algorithm for ligand-receptor docking by giving challenging decoys	Hit finding
CASR	Databank of D-R complexes with numerous atomic lattices and cohesive strength	Hit recognition
Binding DB	An electronic database that accounts for the binding affinity and emphasizes the interplay between drug protein targets with small drug-like entities	ADMET forecasting, hit recognition
MATADOR	Comprehensive information on medicinal uses and adverse drug events. Drug metabolism, target protein pathways.	Hit recognition
PubChem	The chemistry database involves small to large entities with structure, physical characteristics, bioactivities, and patents.	Hit determination, ADMET determination
Tox Ref DB	Having data on in vivo toxicity	ADMET determination
ChEMBL	Database of druggable molecules, consisting of 2D structures, computed properties, and bioactivities	Hit recognition, ADMET forecasting

2.4. AI in human study

SPIRIT-AI is an AI-enabled group of international guidelines for human study protocols. It was co-developed with CONSORT-Ai guidelines. The transparent and complete reporting of study design and protocol is possible with the assistance of SPIRIT-AI. The goal of this AI is

to corroborate the integrity and transparency in clinical trial reporting, which assists the efficacious assessment of AI intervention and helps to ensure their safety and efficacy. (Cruz Rivera et al., 2020; Harrer et al., 2019; Liu et al., 2020)Deep6.ai and IQVIA utilised AI to scan a wide number of electronic health records to recognise the possible candidates for a clinical trial.

2.5. Pharmacoepidemiology and pharmacovigilance

The real-world data is used in PV advanced drug safety assessment by AI techniques. AI interprets and recognizes the unwanted drug events, and upgrades medication-associated problem identification. The AI increased the competency and continuation in processing of personalised case safety reports, dehumanizes the manual processes, eliminates biases, and gives valuable insight for data scientists and medical professionals. (Bate & Hobbiger, 2021; Botsis & Kreimeyer, 2023; Danysz et al., 2019; Lavertu et al., 2021).

CURATE is an AI-enabled program for individualizing medicine that refines therapeutic outcomes by analysing the patient's individual characteristics. The Sentinel system by the FDA uses mechanized algorithms to evaluate the substantial datasets and recognizes probable safety signals related to drugs and other medical products. Another SaaS -based clinical management software by Inovalon, previously known as VigiLanz, is used for clinical monitoring and patient safety solutions. This managed the tedious patient data into relevant and actionable real-time alerts. This software demonstrates its effectiveness for clinicians in finding opportunities to steer clear of or minimize harm, enhance safety, and provide the highest quality of healthcare. Recently, Linguamatics I2E was used to monitor the safety of the COVID-19 vaccine.(Bate & Hobbiger, 2021; Botsis & Kreimeyer, 2023; Danysz et al., 2019; Lavertu et al., 2021).

3. Ethical concerns and challenges

The amalgamation of AI and pharmacology research has boundless opportunities for facilitating clinical results. However, the ethical concerns related to data confidentiality, greediness, fairness, adoption, and integration into clinical settings must be addressed by researchers and stakeholders to guarantee the ethical and responsible use of AI.(Singh et al., 2023). Some ethical concerns and their predictive solution are given in the table 3.

Table 3: Ethical concerns and their solution in utility of AI in pharmacological research

Ethical concerns	Solution
Data confidentiality and security	Prepare an algorithm with the privacy by design principles, enforce strong encryption, control access, follow the protection regulations, and get informed consent from the patient, and data masking at necessary places.
Greediness and fairness concerns in AI	Correct biases during code deployment, Utilise fairness-aware algorithms, employ an overall training program for healthcare workers, and use AI in regular clinical workflow in a user-friendly manner.
Involvement of AI in clinical practice	Identify the technical constraints, conquer organisational hurdles, partner with policy makers, healthcare institutes, and AI developers to develop a friendly environment.

4. Clinical trial and case studies

The pharmaceutical companies are against disclosing their approach to the utilisation of AI for product development. While several companies disclose how they use AI for drug discovery and development (Singh et al., 2023). Representative clinical trails and case studies are represented in table 4

Table 4: Clinical trials and case studies of Ai in pharmacology

Name of company	AI platform	Description
AstraZeneca	Oncoshot	Used to find druggable candidates for clinical trials for chronic kidney disease and idiopathic pulmonary fibrosis
Bayer	Exscientia's AI	Identification of a drug candidate for a new product under the expertise of Bayer
Pfizer	Uses supercomputers, CutoReason, and AI	For studies on COVID-19 vaccines and immune system-related drugs
Sanofi	The Plai Ai platform was developed with Aily Labs.	For drug discovery, trials, and production, this company also developed insulin pens.

5. Future outlook

AI has made a radical change in the domain of pharmacology, with nascent trends including AI, assisted learning, and the amalgamation of AI with blockchain for the hub of medical things (Kolluri et al., 2022; Raza et al., 2022). Approximate dynamic programming will refine drug design by educating agents to increase rewards. It will use the perception of the connection of the drug with the ligand to generate a novel lead molecule possessing desired properties. The security and righteousness of medical data will be ensured by using the integration of blockchain into pharmacological research.

6. Conclusion

AI makes a significant contribution in pharmacology, expanding the field and heightening the number of aspects of drug discovery, development, research, and practice. The huge data analysis, recognition of patents, and predictions can be successfully performed through AI-enabled models such as ML and NLP. It is also associated with empirical data findings, therapeutic drug monitoring, and refining clinical study setups and analysis. Despite the ethical concerns and challenges, AI in pharmacology and medicine holds a valuable position in the field of medicine.

7. Bibliography

Bate, A., & Hobbiger, S. F. (2021). Artificial Intelligence, Real-World Automation and the Safety of Medicines. *Drug Safety*, *44*(2), 125–132. https://doi.org/10.1007/s40264-020-01001-7

Botsis, T., & Kreimeyer, K. (2023). Improving drug safety with adverse event detection using natural language processing. *Expert Opinion on Drug Safety*, *22*(8), 659–668. https://doi.org/10.1080/14740338.2023.2228197

Danysz, K., Cicirello, S., Mingle, E., Assuncao, B., Tetarenko, N., Mockute, R., Abatemarco, D., Widdowson, M., & Desai, S. (2019). Artificial Intelligence and the Future of the Drug Safety Professional. *Drug Safety*, *42*(4), 491–497. https://doi.org/10.1007/s40264-018-0746-z

Dong, J., Wang, N.-N., Yao, Z.-J., Zhang, L., Cheng, Y., Ouyang, D., Lu, A.-P., & Cao, D.-S. (2018). ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. *Journal of Cheminformatics*, *10*(1), 29. https://doi.org/10.1186/s13321-018-0283-x

Dulsat, J., López-Nieto, B., Estrada-Tejedor, R., & Borrell, J. I. (2023). Evaluation of Free Online ADMET Tools for Academic or Small Biotech Environments. *Molecules*, *28*(2), 776. https://doi.org/10.3390/molecules28020776

Gottlieb, A., Stein, G. Y., Ruppin, E., & Sharan, R. (2011). PREDICT: a method for inferring novel drug indications with application to personalized medicine. *Molecular Systems Biology*, *7*(1). https://doi.org/10.1038/msb.2011.26

Kolluri, S., Lin, J., Liu, R., Zhang, Y., & Zhang, W. (2022). Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review. *The AAPS Journal*, *24*(1), 19. https://doi.org/10.1208/s12248-021-00644-3

Lavertu, A., Vora, B., Giacomini, K. M., Altman, R., & Rensi, S. (2021). A New Era in Pharmacovigilance: Toward Real-World Data and Digital Monitoring. *Clinical Pharmacology & Therapeutics*, *109*(5), 1197–1202. https://doi.org/10.1002/cpt.2172

Li, B., Tan, K., Lao, A. R., Wang, H., Zheng, H., & Zhang, L. (2024). A comprehensive review of artificial intelligence for pharmacology research. *Frontiers in Genetics*, *15*. https://doi.org/10.3389/fgene.2024.1450529

Liu, X., Cruz Rivera, S., Moher, D., Calvert, M. J., Denniston, A. K., Chan, A.-W., Darzi, A., Holmes, C., Yau, C., Ashrafian, H., Deeks, J. J., Ferrante di Ruffano, L., Faes, L., Keane, P. A., Vollmer, S. J., Lee, A. Y., Jonas, A., Esteva, A., Beam, A. L., … Rowley, S. (2020). Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. *Nature Medicine*, *26*(9), 1364–1374. https://doi.org/10.1038/s41591-020-1034-x

Martínez Mora, A., Subramanian, V., & Miljković, F. (2022). Multi-task convolutional neural networks for predicting in vitro clearance endpoints from molecular images. *Journal of Computer-Aided Molecular Design*, *36*(6), 443–457. https://doi.org/10.1007/s10822-022-00458-1

Napolitano, F., Zhao, Y., Moreira, V. M., Tagliaferri, R., Kere, J., D'Amato, M., & Greco, D. (2013). Drug repositioning: a machine-learning approach through data integration. *Journal of Cheminformatics*, *5*(1), 30. https://doi.org/10.1186/1758-2946-5-30